The pandemic response roars on
As Regeneron’s antibody cocktail becomes the latest Covid-19 treatment to win US authorisation, Merck shows that the search for new options is not over.
The wait for Astrazeneca’s pivotal Covid-19 vaccine data
As the frontrunners in the Covid-19 vaccine race pull ahead Astra touts promising immunogenicity data in older adults.
Drug rejections rise as Covid-19 bites
Alkermes manages to shrug off yesterday’s complete response letter, but US knockbacks in 2020 are creeping up.
Moderna raises the bar for Covid-19 vaccine efficacy
The first pivotal results with Moderna’s mRNA-based Covid-19 vaccine look even better than those Biontech/Pfizer released a week ago.
A lull in FDA Covid-19 test authorisations
Just as demand for coronavirus tests is peaking, the US regulator has a quiet week.
For severe Covid-19 pin your hopes on antibodies
Failure of BTK inhibition puts the pressure on Lilly, Regeneron and Astrazeneca to deliver with antibodies to treat severe Covid-19.
The pandemic response roars on
As Regeneron’s antibody cocktail becomes the latest Covid-19 treatment to win US authorisation, Merck shows that the search for new options is not over.
The wait for Astrazeneca’s pivotal Covid-19 vaccine data
As the frontrunners in the Covid-19 vaccine race pull ahead Astra touts promising immunogenicity data in older adults.
Drug rejections rise as Covid-19 bites
Alkermes manages to shrug off yesterday’s complete response letter, but US knockbacks in 2020 are creeping up.
Moderna raises the bar for Covid-19 vaccine efficacy
The first pivotal results with Moderna’s mRNA-based Covid-19 vaccine look even better than those Biontech/Pfizer released a week ago.
A lull in FDA Covid-19 test authorisations
Just as demand for coronavirus tests is peaking, the US regulator has a quiet week.
For severe Covid-19 pin your hopes on antibodies
Failure of BTK inhibition puts the pressure on Lilly, Regeneron and Astrazeneca to deliver with antibodies to treat severe Covid-19.
